Nexalin: Nexalin & Greenlight have entered into a partnership

Nexalin Technology, Inc. (Nasdaq: NXL) has not entered into a partnership with Greenlight Financial Technology, Inc. as of May 19, 2026. Instead, Nexalin continues to focus on its development of non-invasive neurostimulation devices for the treatment of mental health and cognitive disorders, including anxiety, insomnia, and Alzheimer’s disease. The company is currently advancing its HALO™ Clarity device through a pivotal clinical trial, which is expected to begin enrolling participants in Q2 2026. This trial is designed to support a planned De Novo FDA submission for the treatment of moderate-to-severe insomnia.

Meanwhile, Greenlight has formed strategic partnerships with financial institutions such as U.S. Bank and Alkami Technology to provide youth-focused financial education and money management tools. These collaborations aim to integrate Greenlight’s debit card and mobile app into the digital banking platforms of financial institutions, offering families a way to teach children responsible financial habits(https://ir.usbank.com/news-events/news/news-details/2024/U.S.-Bank-Greenlight-Partner-to-Bring-Financial-Empowerment-to-Families/default.aspx).

Nexalin and Greenlight operate in distinct sectors—Nexalin in medical technology and Greenlight in fintech—without any indication of a collaborative effort between the two companies. Investors and financial professionals should consider the separate strategic directions and market positions of each firm when evaluating their respective business developments.